We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure (PREVENTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00925470
Recruitment Status : Completed
First Posted : June 22, 2009
Last Update Posted : December 18, 2009
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
Evaluation of target organs impairment on patients suffering from high blood pressure without known cardio vascular or renal disease, stratified on blood pressure control.

Condition or disease
Blood Pressure

Study Type : Observational
Estimated Enrollment : 1200 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure Without Known Cardio Vascular or Renal Disease, Stratified on Blood Pressure Control.
Study Start Date : June 2009
Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources

Group/Cohort
1



Primary Outcome Measures :
  1. To evaluate the frequency of evaluation of target organs preclinical impairment on patients without known cardiovascular or renal disease, taking into consideration the blood pressure level (controlled HBP or not) [ Time Frame: Once ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First 2 consecutive adults with hypertension, without known cardio vascular or renal disease,seen by Cardiologists
Criteria

Inclusion Criteria:

  • Adults with hypertension (treated or not), without known cardiovascular or renal disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00925470


  Show 375 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00925470     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2009/1
First Posted: June 22, 2009    Key Record Dates
Last Update Posted: December 18, 2009
Last Verified: December 2009

Keywords provided by AstraZeneca:
Target organs impairment
High blood pressure
Evaluation of target organs impairment on patients suffering from high blood pressure without known cardiovascular or renal disease

Additional relevant MeSH terms:
Stress, Psychological
Hypertension
Behavioral Symptoms
Vascular Diseases
Cardiovascular Diseases